6533b861fe1ef96bd12c4540

RESEARCH PRODUCT

Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.

Lena PfaffMarlene E ReinckeKarl Heinz WeissChristoph Neumann-haefelinMartin RössleRoman KloecknerLukas SturmHauke HeinzowLara VolkweinCarsten MeyerFelix HahnMichael PraktiknjoKarel CacaAlexander ZipprichMaximilian J. BrolGuohong HanGuohong HanLeon Louis SeifertJonel TrebickaJohannes KluweDominik BettingerFrank Erhard UschnerChristian JansenTobias BoettlerFelix PiechaJan Patrick HuberArthur SchmidtYong LvHendrik LuxenburgerChristoph KlingerChristian RuppRobert ThimmeMichael Schultheiss

subject

0301 basic medicineLiver CirrhosisMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentPopulationClinical Decision-MakingSerum Albumin HumanEsophageal and Gastric Varices03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineAscitesmedicineSecondary PreventionHumanseducationAgedRetrospective Studieseducation.field_of_studyFramingham Risk ScoreHepatologyProportional hazards modelbusiness.industryAge FactorsAscitesBilirubinMiddle Agedmedicine.diseasePrognosisSurvival Rate030104 developmental biologyTreatment OutcomeResearch DesignCreatinineCohortPortal hypertension030211 gastroenterology & hepatologyFemalemedicine.symptomPortasystemic Shunt Transjugular IntrahepaticbusinessGastrointestinal HemorrhageTransjugular intrahepatic portosystemic shunt

description

Background & Aims Transjugular intrahepatic portosystemic shunt (TIPS) implantation is an effective and safe treatment for complications of portal hypertension. Survival prediction is important in these patients as they constitute a high-risk population. Therefore, the aim of our study was to develop an alternative prognostic model for accurate survival prediction after planned TIPS implantation. Methods A total of 1,871 patients with de novo TIPS implantation for ascites or secondary prophylaxis of variceal bleeding were recruited retrospectively. The study cohort was divided into a training set (80% of study patients; n = 1,496) and a validation set (20% of study patients; n = 375). Further, patients with early (preemptive) TIPS implantation due to variceal bleeding were included as another validation cohort (n = 290). Medical data and overall survival (OS) were assessed. A Cox regression model was used to create an alternative prediction model, which includes significant prognostic factors. Results Age, bilirubin, albumin and creatinine were the most important prognostic factors. These parameters were included in a new score named the Freiburg index of post-TIPS survival (FIPS). The FIPS score was able to identify high-risk patients with a significantly reduced median survival of 5.0 (3.1–6.9) months after TIPS implantation in the training set. These results were confirmed in the validation set (median survival of 3.1 [0.9–5.3] months). The FIPS score showed better prognostic discrimination compared to the Child-Pugh, MELD, MELD-Na score and the bilirubin-platelet model. However, the FIPS score showed insufficient prognostic discrimination in patients with early TIPS implantation. Conclusions The FIPS score is superior to established scoring systems for the identification of high-risk patients with a worse prognosis following elective TIPS implantation. Lay summary Implantation of a transjugular intrahepatic portosystemic shunt (TIPS) is a safe and effective treatment for patients with cirrhosis and clinically significant portal hypertension. However, risk stratification is a major challenge in these patients as currently available scoring systems have major drawbacks. Age, bilirubin, albumin and creatinine were included in a new risk score which was named the Freiburg index of post-TIPS survival (FIPS). The FIPS score can identify patients at high risk and may guide clinical decision making.

10.1016/j.jhep.2021.01.023https://pubmed.ncbi.nlm.nih.gov/34265365